Search This Blog

Tuesday, August 8, 2023

CBP officers in Texas seize ‘meth veggies’ worth more than $4 million

 US Customs and Border Protection officers in Texas last week seized more than $4 million worth of methamphetamine concealed inside vegetables.

The bizarre discovery came Friday at the Pharr International Bridge cargo facility in Pharr, Texas. 

CBP officers with the Office of Field Operations encountered a tractor trailer arrived from Mexico. 

An officer referred the vehicle for further inspection.

A physical inspection of the cargo resulted in the discovery of 2,232 packages weighing nearly 500 pounds. 

The packages contained what the CBP officers believe was approximately $4.36 million worth of methamphetamine.

CBP OFO seized the narcotics and the tractor trailer. Special agents with Homeland Security Investigations (HSI) opened a criminal investigation. 

“This massive shipment of narcotics will not make it to American streets thanks to our CBP officers who used their intuition and all our available tools and resources to stop this smuggling attempt,” Port Director Carlos Rodriguez said in a statement. 

“The criminal element continues to attempt to smuggle in the cargo environment, but our CBP officers remain vigilant and will continue to do their best to thwart these smuggling attempts.”

https://nypost.com/2023/08/08/cbp-officers-in-texas-seize-meth-veggies-worth-more-than-4-million/

NY judge blocks new state cannabis licenses after disabled veterans claim discrimination

 A judge has ordered New York regulators not to award any more cannabis licenses pending a decision on an explosive lawsuit alleging officials favored convicted drug felons over disabled veterans to sell legal marijuana.

The Monday decision by Albany state Supreme Court Judge Kevin Bryant came after Gov. Kathy Hochul’s administration was sued last week by four New Yorkers who served in the US Armed Forces.

The lawsuit alleges regulators with the Office of Cannabis Management and state Cannabis Control Board failed to set up a legal cannabis market envisioned by New York’s Marijuana Regulation and Taxation Act (MRTA), which specifically lists disabled vets as one of five priority “social and economic equity” groups to get at least 50% of employment opportunities in the budding pot industry.

A hearing on the case is scheduled for Friday.

“Pending the hearing and determination of this application, defendants, their agents and employees are hereby restrained from awarding or further processing any more CAURD [Conditional Adult-Use Retail Dispensary] licenses … pending further order of this court,” Bryant said in the order.

New York’s first licenses went to “justice involved” individuals or partners of felons convicted of selling marijuana, the suit claims.

Only disabled vets who partnered with someone with a marijuana conviction were awarded a license during the first go-round.

The five groups mentioned are convicted felons of marijuana-related crimes, service-disabled veterans, as well as women and minority-owned businesses and “distressed farmers.”

There are currently 21 state licensed cannabis sellers in the state, nine of which are in New York City.

The procedural ruling by the judge rattled members of the cannabis industry, who have suffered by a slow and rocky rollout after New York legalized marijuana for recreational use in 2021.

NYS Gov. Hochul Cannabis Enforcement Announcement.
New York’s first licenses went to “justice involved” individuals or partners of felons convicted of selling marijuana, the suit claims.
Paul Martinka
An activist smokes marijuana
A hearing on the case is scheduled for Friday.
AFP via Getty Images/ANGELA WEISS
“From now until Friday and if the judge agrees, they [the vet plaintiffs] will have in effect stopped the entire retail market and prevent growing and showcases and new stores like ours from opening,” said Osbert Orduna, founder of the Queens-based The Cannabis Place delivery service.

Orduna is a disabled vet whose partner has a drug conviction.

A spokesman for the disabled vet-plaintiffs declined comment.

https://nypost.com/2023/08/07/judge-blocks-ny-cannabis-licenses-after-vets-claim-discrimination/

NYC officials expect ‘thousands’ of migrant students to arrive in next couple weeks

 Big Apple officials are bracing for “thousands and thousands” more migrants to soon arrive in what’s being described as one of the most challenging waves yet — because it will include a massive amount of kids, City Hall sources said Monday.

State and city education leaders gathered virtually Monday to prepare for the expected huge influx of new students, a well-placed source told The Post.

The noon Zoom meeting was attended by state Education Department Commissioner Betty Rosa, New York City School Chancellor David Banks and other officials scrambling to address the issue as the new school year quickly approaches, according to sources.

During the meeting – which was requested by Rosa, according to a source – there was talk about scattering the onslaught of newly arriving migrant families outside of Gotham in upstate New York communities, the source said.  

“City Hall has been in touch with the governor’s office about how to disperse some of them across counties,” a source said. “The city became aware this morning of a very large influx — thousands and thousands of additional migrants.

David Toledo Latorre from Peru
State and city education leaders gathered to prepare for the expected huge influx of new students.
Stephen Yang
migrants
Officials anticipate more migrants to arrive in the Big Apple.
John Nacion/Shutterstock

“Thousands and thousands are coming within the next couple of weeks,” the source continued.

Officials on the call noted they’re expecting the next batch of migrants to be “one of the biggest influx” that will include many families with school-age children, which will make the latest arrival a more complicated problem for the city and state, the source said.

“That means that some might come into whatever space we have or some the state might say we need to relocate upstate,” the source said.

A City Hall rep said in a statement, “Today, we convened a meeting with representatives from the New York State Department of Education and Governor Hochul’s office to ensure we are coordinating with school districts across the state as we continue to receive large numbers of asylum seeking families each day.

“Our city has gone and continues to go above and beyond to manage this unprecedented humanitarian crisis, and we remain committed to working with our statewide partners to assist these children and families.”

migrants
There was talk about placing migrant families outside of Manhattan in upstate New York.
John Nacion/Shutterstock

In a joint statement, NYS Board of Regents Chancellor Lester Young Jr. and Rosa also said the state Education Department is committed to working with and assisting local governments and educational organizations to ensure relocated migrant families – adults and children – have access to education services.

Gov. Kathy Hochul told reporters last week in Albany that Rosa informed her that some school systems “have capacity more than others” for migrant kids.

“And you also want to make sure that there’s, you know, the proper language skills being taught there,” Hochul said. “English as a second language — you need specialized teachers, so not every school is, lends itself to being the best place for students.

“So there are some schools that have capacity, it would make more sense than others,” the governor said.

Hochul noted her budget earmarked historic levels of funding for education across the state to the tune of $34.5 billion for the 2023-24 school year that could be used on new students from across the border.

https://nypost.com/2023/08/07/nyc-officials-expect-huge-influx-of-migrant-students-to-arrive-in-next-couple-weeks-source/

Monday, August 7, 2023

Why Gracell Is Rising

Shares of Gracell Biotechnologies (GRCL 11.99%) were up by more than 16% as of 2 p.m. on Monday after the clinical-stage biotech company announced a private stock placement of $150 million dollars. The company is scheduled to report second-quarter earnings on Aug. 14. The stock is up more than 75% this year.

The Chinese company focuses on autologous and allogeneic cell therapies to treat cancer and autoimmune disorders. The healthcare company announced on Monday that a private group of investors had agreed to finance the company $100 million up front, plus an additional $50 million tied to the exercise of warrants.

This was good news for two reasons for investors. The financing extends the company's cash situation, allowing it to fund operations into the second half of 2026. Prior to the announcement, the company said it only had $186 million in cash as of the end of the first quarter on March 31. It also shows that investors see potential in the company's lead therapy, GC012F. In June, the company said that GC012F showed an 100% overall response rate in a long-term follow-up to treat patients with relapsed/refractory B-cell non-Hodgkin's lymphoma. The CAR-T therapy is a CD19 and B-cell maturation antigen.

The company has 12 programs in its pipeline, but four of them involve GC012F for different indications, including relapsed/refractory multiple myeloma, newly diagnosed multiple myeloma, B-cell non-Hodgkin lymphoma, and systemic lupus erythematosus, so a lot is riding on the therapy for Gracell. The company also has another CAR-T cell therapy, GC007g, which is in a phase 2 trial in China to treat relapsed/refractory B-cell acute lymphoblastic leukemia and other therapies in preclinical studies. 

https://www.fool.com/investing/2023/08/07/why-shares-of-gracell-biotechnologies-are-rising-m/


Krystal has larger than expected loss

 Stock down after hours on wider than forecast net loss.

https://www.marketscreener.com/quote/stock/KRYSTAL-BIOTECH-INC-37797982/news/Krystal-Biotech-Shares-Fall-After-Wider-Than-Expected-Q2-Net-Loss-44539272/

Human antibody that targets carfentanil, fentanyl, related opioids reverses overdose in preclinical study

 An antibody in single-chain fragment variable (scFv) format that binds to the powerful opioid carfentanil was shown to reverse signs of carfentanil overdose in preclinical tests conducted by scientists at Scripps Research.

Carfentanil is a variant of the synthetic opioid , and about 100 times as potent as its chemical cousin. Along with fentanyl and other fentanyl variants, it is commonly mixed with  such as heroin and cocaine to enhance their euphoric effects, resulting in many fatal overdoses.

In the study, published in ACS Chemical Neuroscience on August 3, 2023, the researchers developed a  that binds very tightly to carfentanil, fentanyl and other fentanyl variants. In rodents, they showed that administering a solution of the antibody shortly after an overdose reverses the potentially deadly  caused by carfentanil, the most dangerous of the variants. The results suggest that the antibody could be a more powerful, longer-lasting treatment for synthetic opioid overdose, compared to existing options.

"We expect this antibody to be a valuable new weapon for fighting the ," says study senior author Kim D. Janda, Ph.D., the Ely R. Callaway, Jr. Professor of Chemistry at Scripps Research.

The study's first author was Lisa Eubanks, Ph.D., a senior staff scientist in the Janda laboratory.

Opioid drugs, whether synthetic or derived from the , bind and activate neuronal receptors called mu-opioid receptors. These receptors are present on different types of neurons across the human nervous system, which is why  have multiple effects like pain-relief and euphoria, but also respiratory depression—slower and shallower breathing. Respiratory depression is the immediate cause of death in the tens of thousands of fatal opioid-related overdoses that occur each year in the U.S.

Carfentanil, after fentanyl, is the next-most common synthetic opioid found in  in the U.S. Once available legally as a tranquilizer for large animals, it was pulled from the market by the FDA in 2018 because of its potential for misuse—and its potential lethality at doses measured in micrograms. Carfentanil is so potent that the U.S. government regards it as a possible chemical warfare agent; the Janda lab's early work on the new antibody was aimed at finding antidotes to such weapons.

Fentanyl and carfentanil overdoses currently are treated with the mu-opioid receptor-blocking drugs naloxone and naltrexone, but these treatments are sometimes ineffective against synthetic opioids even at large doses. Moreover, the benefits of these treatments typically last for less than an hour after dosing—potentially allowing respiratory depression from fentanyl or carfentanil (which persist much longer in the body) to resume.

Janda and his team set out to develop an anti-fentanyl antibody that would have three basic features: Firstly, it should bind with very high affinity to fentanyl and its derivatives, pulling them out of the bloodstream and thereby causing them to diffuse out of the brain as well; secondly, it should persist in the body so as to provide reasonably long-term protection; and thirdly, it should be able to get quickly into the bloodstream and be delivered by a simple intramuscular injection, which requires no special training.

To obtain antibodies, Janda and his team vaccinated rodents with a molecule they designed that would elicit antibodies against carfentanil, fentanyl and variants. The rodents were engineered to produce human antibodies (rather than rodent antibodies, which would trigger an unwanted immune response if administered to humans). Among the resulting antibodies, the researchers were able to identify several that bind to carfentanil with super-high affinity—and bind very strongly to fentanyl and several other fentanyl derivatives. They then selected the most potent of these antibodies, modified it to be more lightweight (so that it would get quickly into the bloodstream), and further altered it so it would persist in the blood for days.

Tests in rodents showed that the optimized scFv, dubbed C10‐S66K, did indeed have a powerful effect at reducing carfentanil's actions on the brain—reversing carfentanil-driven respiratory depression when injected 15 minutes after a heavy carfentanil exposure. The effect after about 40 minutes was stronger than naloxone's and was still increasing after two hours, whereas naloxone's peaked at 30 minutes and swiftly declined.

As part of the study, the collaborating laboratory of Ian Wilson, Ph.D., Hansen Professor of Structural Biology at Scripps Research, used X-ray crystallography to determine the near-atomic resolution structures of carfentanil- and fentanyl-bound C10‐S66K. These structural data suggest that the antibody should indeed bind well to multiple fentanyl derivatives but should not interfere with the activity of other beneficial opioid molecules such as naloxone and naltrexone.

The U.S. Food and Drug Administration (FDA) has approved a full length IgG version of this antibody termed CSX-1004 for clinical trials, slated to begin this month for the prevention of fentanyl overdose.

More information: Lisa M. Eubanks et al, An Engineered Human-Antibody Fragment with Fentanyl Pan-Specificity That Reverses Carfentanil-Induced Respiratory Depression, ACS Chemical Neuroscience (2023). DOI: 10.1021/acschemneuro.3c00455


https://medicalxpress.com/news/2023-08-human-antibody-carfentanil-fentanyl-opioids.html

Brain's 'appetite control center' different in overweight or obese

 Cambridge scientists have shown that the hypothalamus, a key region of the brain involved in controlling appetite, is different in the brains of people who are overweight and people with obesity when compared to people who are a healthy weight.

The researchers say their findings add further evidence to the relevance of  structure to weight and food consumption.

Current estimations suggest that over 1.9 billion people worldwide are either overweight or obese. In the UK, according to the Office for Health Improvement & Disparities, almost two-thirds of adults are overweight or living with obesity. This increases an individual's risk of developing a number of health problems, including type 2 diabetes, heart disease and stroke, cancer and poorer mental health.

A large number of factors influence how much we eat and the types of food we eat, including our genetics, hormone regulation, and the environment in which we live. What happens in our brains to tell us that we are hungry or full is not entirely clear, though studies have shown that the hypothalamus, a small region of the brain about the size of an almond, plays an important role.

Dr. Stephanie Brown from the Department of Psychiatry and Lucy Cavendish College, University of Cambridge, said, "Although we know the hypothalamus is important for determining how much we eat, we actually have very little direct information about this brain region in living humans. That's because it is very small and hard to make out on traditional MRI brain scans."

The majority of evidence for the role of the hypothalamus in appetite regulation comes from animal studies. These show that there are complex interacting pathways within the hypothalamus, with different cell populations acting together to tell us when we are hungry or full.

To get around this, Dr. Brown and colleagues used an algorithm developed using machine learning to analyze MRI brain scans taken from 1,351 young adults across a range of BMI scores, looking for differences in the hypothalamus when comparing individuals who are underweight, healthy weight, overweight and living with obesity.

In a study published in Neuroimage: Clinical, the team found that the overall volume of the hypothalamus was significantly larger in the overweight and obese groups of young adults. In fact, the team found a  between volume of the hypothalamus and  (BMI).

These volume differences were most apparent in those sub-regions of the hypothalamus that control appetite through the release of hormones to balance hunger and fullness.

While the precise significance of the finding is unclear—including whether the structural changes are a cause or a consequence of the changes in —one possibility is that the change relates to inflammation. Previous animal studies have shown that a  can cause inflammation of the hypothalamus, which in turn prompts insulin resistance and obesity.

In mice, just three days of a fat-rich diet is enough to cause this inflammation. Other studies have shown that this inflammation can raise the threshold at which animals are full—in other words, they have to eat more food than usual to feel full.

Dr. Brown, the study's first author, added, "If what we see in mice is the case in people, then eating a high-fat diet could trigger inflammation of our appetite control center. Over time, this would change our ability to tell when we've eaten enough and to how our body processes blood sugar, leading us to put on weight."

Inflammation may explain why the hypothalamus is larger in these individuals, the team say. One suggestion is that the body reacts to inflammation by increasing the size of the brain's specialist immune cells, known as glia.

Professor Paul Fletcher, the study's senior author, from the Department of Psychiatry and Clare College, Cambridge, said, "The last two decades have given us important insights about appetite control and how it may be altered in obesity. Metabolic researchers at Cambridge have played a leading role in this."

"Our hope is that by taking this new approach to analyzing brain scans in large datasets, we can further extend this work into humans, ultimately relating these subtle structural brain findings to changes in appetite and eating and generating a more comprehensive understanding of obesity."

The team say more research is needed to confirm whether increased volume in the  is a result of being overweight or whether people with larger hypothalami are predisposed to eat more in the first place. It is also possible that these two factors interact with each other causing a feedback loop.

More information: Stephanie S.G. Brown Conceptualisation et al, Hypothalamic volume is associated with body mass index, NeuroImage: Clinical (2023). DOI: 10.1016/j.nicl.2023.103478


https://medicalxpress.com/news/2023-08-brain-appetite-center-people-overweight.html